November 7, 2022 - Sandoz, a global leader in generic and biosimilar medicines, today announced an additional investment of EUR 50 million to support increased European manufacturing capacity for finished dosage form (FDF) penicillins, the leading class of antibiotics worldwide.
Homepage
Explore Novartis
À propos de nous
Notre travail
Carrières
Sandoz is een wereldleider op het gebied van generische geneesmiddelen en biosimilars
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
Novartis Financial Results – Q3 2022
Service d'éducation médicale
Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics. The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®)) in more than 100 markets.
Sandoz officially certified as Global Top Employer 2021
Sandoz, a Novartis division, is pleased to announce that it has been officially awarded “Global Top Employer 2021” certification for the third year in a row. This year, Sandoz was one of only 16 Top Employers recognized for their outstanding HR policies and practices worldwide by the Top Employers Institute.
Sandoz fait don d’hydroxychloroquine à la Belgique
Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie du COVID-19. La Belgique est l'un des nombreux pays à bénéficier de ce don.